Hydrogenics Announces Pricing and Upsizing of Public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hydrogenics Announces Pricing and Upsizing of Public Offering of Common Shares

MISSISSAUGA, Ontario, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Hydrogenics Corporation (NASDAQ: HYGS ) (TSX: HYG ) (the "Company") today announced the pricing of its previously announced underwritten public offering of 2,129,031 common shares (the "Offering") at a price of $7.75 per share. Net proceeds to the Company from the Offering are expected to be approximately $15,276,000, after deducting underwriting commissions and other expenses related to the Offering and assuming no exercise of the underwriters' overallotment option. Based upon pricing and investor demand, the Company elected to increase the size of the Offering from the previously announced $15 million to $16.5 million. The Company has also granted to the underwriters a 30-day option to purchase up to an additional 319,354 common shares to cover overallotments in connection with the Offering.

Craig-Hallum Capital Group LLC is acting as sole book-running manager for the Offering. Roth Capital Partners is acting as co-manager for the Offering.

The Offering is expected to close on or about December 16, 2015, subject to customary closing conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approvals of the Toronto Stock Exchange and the NASDAQ Global Market.

The Company intends to use its net proceeds from the Offering primarily for general corporate purposes, including to support any negative cash flows from operating activities.

The Offering is being conducted pursuant to the Company's effective shelf registration statement on Form F-10 filed with the U.S. Securities and Exchange Commission (the "SEC"). The offering will be made only by means of a preliminary prospectus supplement, a final prospectus supplement and the accompanying short form base shelf prospectus. Copies of the preliminary prospectus supplement, and when available, the final prospectus supplement and the accompanying short form base shelf prospectus may be obtained from Craig-Hallum Capital Group, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, telephone 612-334-6300, email: prospectus@chlm.com. Electronic copies of the preliminary prospectus supplement, the final prospectus supplement and the accompanying short form base shelf prospectus will also be available free of charge on the SEC's website at www.sec.gov .

The common shares in the Offering will not be qualified for sale under the securities laws of Canada or any province or territory of Canada and are not being offered for sale in Canada or to any resident of Canada. The Company is relying on the exemption set forth in Section 602.1 of the Company Manual of the TSX which exemption provides that the TSX will not apply certain of its standards to eligible interlisted issuers.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Hydrogenics

Hydrogenics Corporation is a world leader in engineering and building the technologies required to enable the acceleration of a global power shift. Headquartered in Mississauga, Ontario, Hydrogenics provides hydrogen generation, energy storage and hydrogen power modules to its customers and partners around the world. Hydrogenics has manufacturing sites in Germany, Belgium and Canada and service centres in Russia, Europe, the US and Canada.

Forward-looking Statements

This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management's current expectations and actual results may differ from these forward-looking statements due to numerous factors, including: our inability to increase our revenues or raise additional funding to continue operations, execute our business plan, or to grow our business; inability to address a slow return to economic growth, and its impact on our business, results of operations and consolidated financial condition; our limited operating history; inability to implement our business strategy; fluctuations in our quarterly results; failure to maintain our customer base that generates the majority of our revenues; currency fluctuations; failure to maintain sufficient insurance coverage; changes in value of our goodwill; failure of a significant market to develop for our products; failure of hydrogen being readily available on a cost-effective basis; changes in government policies and regulations; failure of uniform codes and standards for hydrogen fuelled vehicles and related infrastructure to develop; liability for environmental damages resulting from our research, development or manufacturing operations; failure to compete with other developers and manufacturers of products in our industry; failure to compete with developers and manufacturers of traditional and alternative technologies; failure to develop partnerships with original equipment manufacturers, governments, systems integrators and other third parties; inability to obtain sufficient materials and components for our products from suppliers; failure to manage expansion of our operations; failure to manage foreign sales and operations; failure to recruit, train and retain key management personnel; inability to integrate acquisitions; failure to develop adequate manufacturing processes and capabilities; failure to complete the development of commercially viable products; failure to produce cost-competitive products; failure or delay in field testing of our products; failure to produce products free of defects or errors; inability to adapt to technological advances or new codes and standards; failure to protect our intellectual property; our involvement in intellectual property litigation; exposure to product liability claims; failure to meet rules regarding passive foreign investment companies; actions of our significant and principal shareholders; dilution as a result of significant issuances of our common shares and preferred shares; inability of US investors to enforce US civil liability judgments against us; volatility of our common share price; and dilution as a result of the exercise of options. Readers should not place undue reliance on Hydrogenics' forward-looking statements. Investors are encouraged to review the section captioned "Risk Factors" in Hydrogenics' regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics' future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

Investor Contacts: Bob Motz, Chief Financial Officer (905) 361-3660 Chris Witty Hydrogenics Investor Relations (646) 438-9385

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 158

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 119

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 183

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 211

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 138

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 365

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 139

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading

Top 5 Most Recently Viewed Articles

BlueLinx Expands Its Reach with New Portland Distribution Hub

Updated Category News Views 147

BlueLinx Unveils New Distribution Center in Portland BlueLinx Holdings Inc. (NYSE: BXC) has officially opened a greenfield distribution center in Portland, enhancing its operational footprint in the Pacific Northwest. This facility is a significant addition to the company’s distribution capabilities, as it strategically positions BlueLinx to serve the growing demands of...

Continue Reading
IBA Partners with China Gold to Advance X-ray Technological Growth

Updated Category News Views 255

Strategic Partnership for Industry Advancement In a significant move for the irradiation processing industry, IBA (Ion Beam Applications S.A., EURONEXT) has joined forces with China Gold Irradiation (CGI), the premier irradiation service provider in China. This collaboration is set to elevate the standards of irradiation services by incorporating advanced X-ray...

Continue Reading
Amerant Bank and Partners Generate Support for Local Charity

Updated Category News Views 189

Generous Collaboration: Amerant Bank's Community Impact In a heartwarming display of community spirit, Amerant Bank has partnered with Sedano’s Supermarkets and Fresco y Más to make a significant difference in the lives of underserved children and families. The culmination of their efforts was marked by a grand check presentation to Centro Mater, a renowned...

Continue Reading
Mediar Therapeutics Advances Phase 2 Trial for Rare Lung Disease

Updated Category News Views 123

Mediar Therapeutics Initiates Phase 2 WISPer Trial Mediar Therapeutics, Inc., a pioneering clinical-stage biotechnology company, has reached a major milestone by dosing the first patient in its Phase 2 WISPer clinical trial. This trial focuses on evaluating MTX-463, a first-in-class therapy designed to combat idiopathic pulmonary fibrosis (IPF). The primary goal of this...

Continue Reading
Chime Biologics and Waterstone Unite for ADC Innovation

Updated Category News Views 242

Chime Biologics and Waterstone Forge a New Path in ADC Development Chime Biologics and Waterstone Pharmaceuticals have officially announced a strategic partnership designed to enhance the capabilities and efficiencies within the Antibody-Drug Conjugate (ADC) industry. By combining their expertise, both companies aim to provide integrated services that boost the...

Continue Reading